The effective use of targeted therapy is highly dependent on the identification of responder patient populations. Loss of FBW7, which encodes a tumour-suppressor protein, is frequently found in various types of human cancer, including breast cancer, colon cancer 1 and T-cell acute lymphoblastic leukaemia (T-ALL) 2 . In line with these genomic data, engineered deletion of Fbw7 in mouse T cells results in T-ALL 3-5 , validating FBW7 as a T-ALL tumour suppressor. Determining the precise molecular mechanisms by which FBW7 exerts antitumour activity is an area of intensive investigation. These mechanisms are thought to relate in part to FBW7-mediated destruction of key proteins relevant to cancer, including Jun 6 , Myc 7 , cyclin E 8 and notch 1 (ref. 9), all of which have oncoprotein activity and are overexpressed in various human cancers, including leukaemia. In addition to accelerating cell growth 10 , overexpression of Jun, Myc or notch 1 can also induce programmed cell death 11 . Thus, considerable uncertainty surrounds how FBW7-deficient cells evade cell death in the setting of upregulated Jun, Myc and/or notch 1. Here we show that the E3 ubiquitin ligase SCF FBW7 (a SKP1-cullin-1-F-box complex that contains FBW7 as the F-box protein) governs cellular apoptosis by targeting MCL1, a pro-survival BCL2 family member, for ubiquitylation and destruction in a manner that depends on phosphorylation by glycogen synthase kinase 3. Human T-ALL cell lines showed a close relationship between FBW7 loss and MCL1 overexpression. Correspondingly, T-ALL cell lines with defective FBW7 are particularly sensitive to the multi-kinase inhibitor sorafenib but resistant to the BCL2 antagonist ABT-737. On the genetic level, FBW7 reconstitution or MCL1 depletion restores sensitivity to ABT-737, establishing MCL1 as a therapeutically relevant bypass survival mechanism that enables FBW7-deficient cells to evade apoptosis. Therefore, our work provides insight into the molecular mechanism of direct tumour suppression by FBW7 and has implications for the targeted treatment of patients with FBW7-deficient T-ALL.
The effective use of targeted therapy is highly dependent on the identification of responder patient populations. Loss of FBW7, which encodes a tumour-suppressor protein, is frequently found in various types of human cancer, including breast cancer, colon cancer 1 and T-cell acute lymphoblastic leukaemia (T-ALL) 2 . In line with these genomic data, engineered deletion of Fbw7 in mouse T cells results in T-ALL [3] [4] [5] , validating FBW7 as a T-ALL tumour suppressor. Determining the precise molecular mechanisms by which FBW7 exerts antitumour activity is an area of intensive investigation. These mechanisms are thought to relate in part to FBW7-mediated destruction of key proteins relevant to cancer, including Jun 6 , Myc 7 , cyclin E 8 and notch 1 (ref. 9) , all of which have oncoprotein activity and are overexpressed in various human cancers, including leukaemia. In addition to accelerating cell growth 10 , overexpression of Jun, Myc or notch 1 can also induce programmed cell death 11 . Thus, considerable uncertainty surrounds how FBW7-deficient cells evade cell death in the setting of upregulated Jun, Myc and/or notch 1. Here we show that the E3 ubiquitin ligase SCF FBW7 (a SKP1-cullin-1-F-box complex that contains FBW7 as the F-box protein) governs cellular apoptosis by targeting MCL1, a pro-survival BCL2 family member, for ubiquitylation and destruction in a manner that depends on phosphorylation by glycogen synthase kinase 3. Human T-ALL cell lines showed a close relationship between FBW7 loss and MCL1 overexpression. Correspondingly, T-ALL cell lines with defective FBW7 are particularly sensitive to the multi-kinase inhibitor sorafenib but resistant to the BCL2 antagonist ABT-737. On the genetic level, FBW7 reconstitution or MCL1 depletion restores sensitivity to ABT-737, establishing MCL1 as a therapeutically relevant bypass survival mechanism that enables FBW7-deficient cells to evade apoptosis. Therefore, our work provides insight into the molecular mechanism of direct tumour suppression by FBW7 and has implications for the targeted treatment of patients with FBW7-deficient T-ALL.
MCL1 is frequently overexpressed in various leukaemias through mechanisms that are not fully understood 12 . MCL1 is distinct from other BCL2 family members in its extremely unstable nature 13 , which provides a mechanism for cells to switch to either survival or apoptotic mode in response to various stresses 14 . Phosphorylation of MCL1 by glycogen synthase kinase 3 (GSK3) regulates the stability of MCL1 (ref. 13 ), but little is known about the identity of the E3 ubiquitin ligase that targets phosphorylated MCL1 for destruction. On examination of the GSK3-mediated phosphorylation sites in MCL1, we surmised that they resemble a degron sequence that can be recognized by FBW7 (also known as FBXW7) ( Fig. 1a ), prompting us to test the possibility that GSK3-mediated phosphorylation of MCL1 triggers the degradation of MCL1 by FBW7. Depletion of FBW7 ( Fig. 1b ) or the SCF components cullin 1 (CUL1), RBX1 and SKP1 ( Fig. 1c ), but not other F-box proteins that we examined ( Fig. 1b ), resulted in a significant increase in the amount of MCL1 protein. T-cell-lineage-specific depletion of FBW7 in Fbw7 conditional knockout (Lck-Cre/Fbw7 fl/fl )mice 3 resulted in increased MCL1 levels in the thymuses of these mice ( Fig. 1d ), as well as thymic lymphoma ( Supplementary Fig. 1a ) and the presence of acute leukaemia cells in the thymuses ( Supplementary Fig. 1b ). Consistent with a recent study 15 , FBW7 2/2 human DLD1 cells ( Fig. 1e ) and HeLa cells treated with short interfering RNA (siRNA) directed against FBW7 ( Supplementary Fig. 1c ) have elevated MCL1 expression mainly in the mitosis (M) and early G1 phases of the cell cycle.
The clinical relevance of this finding is further demonstrated by the finding that human T-ALL cell lines harbouring FBW7 mutations and/ or deletions have a significant increase in MCL1 ( Fig. 1f ). Additionally, depletion of FBW7 in DND41 cells or Loucy cells (both of which have wild-type FBW7) leads to increased MCL1 expression ( Fig. 1g ), whereas reintroduction of wild-type FBW7 dramatically reduced MCL1 expression in FBW7-deficient T-ALL cells ( Fig. 1h ), supporting a causal relationship between loss of FBW7 activity and elevated MCL1 expression in the T-ALL cells examined. More importantly, elevated MCL1 expression is also observed in both primary human and mouse T-ALL samples with deficient FBW7 activity [2] [3] [4] (Fig. 1i , j and Supplementary Fig. 1a , b), and depletion of MCL1 impaired T-ALL disease progression in vivo ( Fig. 1k-m) .
Consistent with a post-translational mode of regulation, no changes in MCL1 mRNA levels were observed after depletion of FBW7 in DLD1 cells ( Supplementary Fig. 2d ), and no positive relationship was observed between MCL1 mRNA levels and loss of FBW7 in T-ALL cells ( Supplementary Fig. 2e ). The half-life of MCL1 was significantly extended in the thymuses of Fbw7 2/2 mice and FBW7-deficient human T-ALL cells ( Supplementary Fig. 3a -c), and experimental manipulation of FBW7 levels changed MCL1 stability accordingly ( Supplementary Fig. 3d, e ). Together, these results suggest that MCL1 is a downstream ubiquitylation target of SCF FBW7 .
As the proper substrate phosphorylation events are required for FBW7 to recognize and target its substrates for ubiquitylation 16 , we next investigated which phosphorylation events trigger MCL1 destruction by FBW7. Mass spectrometry analysis showed that MCL1 is phosphorylated at multiple sites in vivo ( Fig. 2a and Supplementary  Fig. 5a -c). In addition to serine at position 159 (S159) and threonine at position 163 (T163) 13, 17 , S64 and S121 were also phosphorylated in vivo. Consistent with previous reports 13, 17 , MCL1 destruction is promoted by GSK3 ( Fig. 2b) but not by the protein kinases ERK1 (also known as MAPK3) and/or ERK2 (also known as MAPK1) (Supplementary Fig. 5d -f). To investigate further the significance of each individual phosphorylation site, we created a panel of MCL1 mutants ( Fig. 2c ). Using in vitro kinase assays, we identified S159 and T163 as the major GSK3-mediated phosphorylation sites 17 and S121 as a minor GSK3-mediated phosphorylation site ( Human T-ALL cell line
Human T-ALL cell line . For the histogram, MCL1 band intensity was normalized to HSP90 and then normalized to the control lane. Data are shown as mean 6 s.e.m. for three independent experiments. e, IB analysis of wild-type (WT) and FBW7 2/2 DLD1 cells after synchronization of the cell cycles with nocodazole and release from mitotic arrest at the indicated time points. pS9-GSK3, GSK3 that is phosphorylated at the S9 residue. f, IB analysis of the indicated human T-ALL cell lines, which have either WT FBW7 or mutant FBW7 (a deletion (Del) or an amino acid substitution). g, The human T-ALL cell lines DND41 and Loucy cells, which contain wild-type FBW7, were infected with the indicated lentiviral shRNA constructs and selected with 1 mg ml 21 puromycin to eliminate the non-infected cells. Cell lysates were collected for IB analysis. shFBW7, shRNA specific for FBW7; shGFP, shRNA specific for the gene encoding green fluorescent protein (GFP). h, Human T-ALL cell lines deficient in FBW7 were infected with an FBW7-expressing retroviral construct (with empty vector (EV) as a negative control) and selected with 1 mg ml 21 puromycin to eliminate the non-infected cells. Cell lysates were collected for IB analysis. HA, haemagglutinin tag. i, IB analysis of the indicated primary human T-ALL clinical samples. j, IB analysis of the indicated mouse T-ALL cell lines derived from Fig. 5g ). Inactivation of these GSK3-mediated phosphorylation sites impairs the interaction between MCL1 and FBW7 both in vitro ( Fig. 2f and Supplementary Fig. 5h ) and in vivo ( Fig. 2g and Supplementary  Fig. 5i ). Furthermore, pharmacological inhibition of GSK3 activity blocked the interaction between HA-tagged FBW7 and endogenous MCL1 ( Fig. 2h ) and inhibited the localization of FBW7 to the mitochondria, where MCL1 resides ( Supplementary Fig. 5j, k) . These results indicate that GSK3-dependent phosphorylation of MCL1 is necessary for the interaction of MCL1 with FBW7. Consistent with this FBW7-MCL1 regulatory axis, MCL1 specifically interacts with FBW7 ( Supplementary Fig. 6a , b, j-l) and CUL1 ( Supplementary  Fig. 6c, d) , and depletion of endogenous CUL1 increases MCL1 abundance ( Supplementary Fig. 11a ). We next explored the mechanism by which FBW7 alters MCL1 stability. Overexpression of FBW7 and GSK3 significantly decreased MCL1 abundance ( Fig. 3a and Supplementary Fig. 6h ), whereas inactivation of the major GSK3-dependent phosphorylation sites on MCL1 impaired FBW7-mediated destruction ( Fig. 3b and Supplementary Fig. 6e -g). All FBW7 isoforms (particularly the a-isoform and the c-isoform) participate in MCL1 stability control, and FBW7 dimerization is not required for the degradation of MCL1 ( Supplementary Fig.  7a-e ). Mutant FBW7 constructs derived from patients with T-ALL showed a reduced ability to interact with MCLl ( Supplementary Fig.  6i ) and were therefore unable to degrade MCL1 (Fig. 3c) . Moreover, the FBW7-and GSK3-mediated destruction of MCL1 was blocked by the proteasome inhibitor MG132, indicating the involvement of the ubiquitin-proteasome pathway in this process (Fig. 3a) . In support of this idea, co-expression of GSK3 and FBW7 resulted in a marked reduction in the half-life of wild-type MCL1, but not of the 2A or 3A MCL1 mutants (Fig. 3d) , with reduced interaction with FBW7 S159/T163  2A  3A  S64/T68  S121  S150/T154   FBW7 consensus   167  151  167  167  72  56  129  113  161 and GSK3B with a single siRNA and GSK3a 1 GSK3b indicates depletion with siRNAs targeting each gene separately). c, Illustration of the various MCL1 mutants generated for this study. Conserved serine and threonine residues within the degron sequence are shown in red, and conserved proline residues are shown in blue. 2A, MCL1 S159A/T163A; 3A, MCL1 S155A/S159A/T163A. d, e, GSK3 phosphorylates MCL1 in vitro at multiple sites. Purified GSK3 protein was incubated with 5 mg of the indicated glutathione S-transferase (GST)-MCL1 fusion proteins (top, WT and mutant as in c) in the presence of [c-32 P]ATP. The protein kinase reaction products were resolved by SDS-PAGE, and phosphorylation was detected by autoradiography. f, Phosphorylation of MCL1 at multiple sites by GSK3 triggers the interaction of MCL1 with FBW7 in vitro. Autoradiograms show recovery of 35 S-labelled FBW7 protein bound to the indicated GST-MCL1 fusion proteins (with GST protein as a negative control) incubated with GSK3 before the pull-down assays. g, IB analysis of whole-cell lysates (WCL) and immunoprecipitates (IP) derived from 293T cells transfected with HA-FBW7 together with the indicated Myc-MCL1 constructs (top). Thirty hours after transfection, cells were pretreated with 10 mM MG132 for 10 h to block the proteasome pathway before cell collection. h, IB analysis of WCL and IP derived from 293T cells transfected with HA-FBW7. Thirty hours after transfection, cells were pretreated with 20 mM MG132 for 8 h to block the proteasome pathway before cell collection. Where indicated, 25 mM GSK3b inhibitor VIII (with dimethylsulphoxide (DMSO) as a negative control) was added for 8 h before cell collection.
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RESEARCH LETTER ( Fig. 2g ). Furthermore, loss of FBW7 extends the half-life of endogenous MCL1 (Fig. 3e) , and FBW7 promotes the ubiquitylation of MCL1 in a GSK3-dependent manner ( Fig. 3f and Supplementary Fig. 8a, b, e ). The decrease of MCL1 expression is also impaired in response to various DNA-damaging agents 18 in FBW7 2/2 DLD1 cells ( Fig. 3g and Supplementary Fig. 8f ). Together, these data suggest a physiological role for FBW7 in promoting MCL1 destruction in vivo in a GSK3-mediated phosphorylation-dependent manner. Next, we explored how FBW7 affects the cellular apoptotic response by modulating MCL1 abundance. As predicted, Fbw7 2/2 mouse thymocytes and FBW7-deficient human T-ALL cells with increased MCL1 levels were less sensitive to apoptotic stimuli ( Supplementary  Fig. 9a-f ). More interestingly, compared with T-ALL cell lines that had wild-type FBW7, FBW7-deficient T-ALL cells with elevated MCL1 expression ( Fig. 1f and Supplementary Fig. 9h ) were more sensitive to the multi-kinase inhibitor sorafenib, which can effectively reduce MCL1 expression 19, 20 (Fig. 4a and Supplementary Fig. 9g-i) . Although the ability of sorafenib to repress MCL1 has been attributed to the inactivation of the RAF-ERK pathway and/or the activation of GSK3 activity 19 , the exact mechanism remains unclear. Nonetheless, these data suggest that FBW7-deficient T-ALL cell lines might require elevated levels of MCL1 to evade apoptosis, a phenotype known as 'oncogene addiction' 21 . By contrast, FBW7-deficient T-ALL cell lines were more resistant to ABT-737 ( Fig. 4a and Supplementary Fig. 9g, j) . ABT-737 is a BH3 domain mimetic and a pan inhibitor of the BCL2 family of anti-apoptotic proteins, and it is reported to kill leukaemia cells effectively 22 . However, leukaemia cells with elevated MCL1 levels are refractory to treatment with ABT-737 (refs 23, 24), primarily because ABT-737 fails to inactivate MCL1 (ref. 22 ). Experimental evidence from both double staining with 7-amino-actinomycin D (7-AAD) and annexin V ( Supplementary Fig. 9j ) and immunoblotting specific for apoptotic biomarkers (Fig. 4b) suggests that ABT-737induced apoptosis is impaired in FBW7-deficient T-ALL cells. Moreover, specific depletion of MCL1 in multiple FBW7-deficient T-ALL cell lines restored the sensitivity of these cells to ABT-737 ( Fig. 4c, d) , supporting the idea that increased MCL1 expression is GSK3-mediated phosphorylation-dependent manner. a-c, GSK3-mediated phosphorylation-dependent degradation of MCL1 by FBW7. IB analysis of 293T cells transfected with plasmids expressing the indicated Myc-MCL1 and HA-FBW7 proteins in the presence or absence of HA-GSK3 (top), with antibodies specific for the Myc tag, HA tag, GFP or tubulin (right). A plasmid encoding GFP was used as a negative control for transfection efficiency. Where indicated, the proteasome inhibitor MG132 was added. d, 293T cells were transfected with the indicated Myc-MCL1 constructs together with the HA-FBW7-and HA-GSK3-expressing plasmids. Twenty hours after transfection, cells were split into 60-mm dishes. After another 20 h, cells were treated with 20 mg ml 21 cycloheximide (CHX). At the indicated time points, WCL were prepared, and IB analysis was carried out with antibodies specific for the indicated proteins. e, Top, WT or FBW7 2/2 DLD1 cells were treated with 20 mg ml 21 CHX. At the indicated time points, WCL were prepared, and IB analysis was carried out with antibodies specific for the indicated proteins. Bottom, MCL1 band intensity was normalized to tubulin and then normalized to the t 5 0 controls. f, IB of WCL and His tag pull-down of HeLa cells transfected with plasmids expressing the indicated proteins. Twenty hours after transfection, cells were treated with the proteasome inhibitor MG132 for 12 h before cell collection. His tag pull-down was performed in the presence of 8 M urea to eliminate any possible contamination from MCL1-associated proteins. Ni-NTA, nickel-nitrilotriacetic acid; Ub, ubiquitin. g, Top, IB analysis of WT and FBW7 2/2 DLD1 cells treated with 10 mM adriamycin (ADR) for the indicated time durations. Bottom, MCL1 band intensity was normalized to tubulin and then normalized to the t 5 0 controls.
the primary cause of desensitization to ABT-737 in vivo 23, 24 . It also suggests that patients with FBW7-deficient T-ALL will not respond well to treatment with ABT-737. We further demonstrated that manipulation of FBW7 activity or ectopic expression of a non-degradable form of MCL1 in human T-ALL cells affects their sensitivity to ABT-737 ( Supplementary Fig. 10a, b ) and responses to other apoptotic stimuli ( Supplementary Fig. 10c-f ).
Our results indicate that inhibition of MCL1 could be used to restore sensitivity to ABT-737 in FBW7-deficient T-ALL cells. Given that the clinical application of siRNA-or short hairpin RNA (shRNA)-mediated target extinction is not yet feasible owing to delivery challenges, we instead exploited small molecule strategies to reduce MCL1 expression, specifically with the use of sorafenib ( Supplementary Fig. 9h ). The combined use of sorafenib and ABT-737 produced a dose-dependent Various T-ALL cell lines were infected with lentiviral shGFP-or shMCL1-encoding vectors and selected in 0.5 mg ml 21 puromycin to eliminate non-infected cells. The generated cell lines were cultured in 10% FBScontaining medium with the indicated concentrations of ABT-737 for 48 h before cell viability assays were performed (right) or with or without ABT-737 (0.8 mM) treatment for 24 h before WCL were collected for IB analysis with antibodies specific for the indicated proteins (left). For cell viability assays, data are shown as mean 6 s.d. for three independent experiments. d, Double staining with 7-AAD and annexin-V-PE (annexin V conjugated to phycoerythrin), followed by flow cytometry analysis to detect the percentage of apoptotic cells (axes indicate intensity of fluorochrome). In the indicated FBW7-deficient human T-ALL cell lines, endogenous MCL1 was depleted by infection with lentiviral vectors encoding shRNA (lentiviral shGFP was used as a negative control). Cell lines were cultured in 10% FBS-containing medium with or without ABT-737 (0.8 mM) treatment, with DMSO as a negative control, for 48 h before the flow cytometry analysis. Purple numbers indicate the percentage of apoptotic cells. e, Staining and flow cytometry analysis as in d, demonstrating that sorafenib treatment restores ABT-737 sensitivity to FBW7-deficient HPB-ALL cells. HPB-ALL cells were cultured in 10% FBScontaining medium with the indicated concentrations of sorafenib and/or ABT-737 for 48 h before analysis. Coloured numbers indicate the percentage of apoptotic cells.
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increase in the sensitivity of HPB-ALL cells, a human T-ALL cell line, to ABT-737 ( Supplementary Fig. 10g ), and this decrease correlated with a significant increase in the induction of apoptosis (Fig. 4e ). Similar results were obtained for other FBW7-deficient T-ALL cell lines ( Supplementary Fig. 10h ).
Our studies provide experimental evidence of a role for FBW7 in governing the apoptotic pathway by controlling MCL1 destruction. MCL1 has a key role in regulating the apoptosis of T cells 14 but not of cells from other tissue types, such as liver cells. Therefore, our studies also provide a possible mechanistic explanation for why loss of FBW7 is frequently seen in patients with T-ALL. Although other E3 ubiquitin ligases, including MULE 25 and b-transducin-repeat-containing protein (b-TRCP) 17 , have been implicated in controlling MCL1 stability, MULE activity was not implicated in the GSK3-dependent regulation of MCL1 (refs 17, 25) ( Supplementary Fig. 11a-e ). Additionally, no correlation was found between MULE and MCL1 expression in various T-ALL cells ( Supplementary Fig. 11f ), thereby excluding a physiological role for MULE in regulating MCL1 abundance in T-ALL cells. We further found that depletion of FBW7, but not b-TRCP, leads to a significant induction of MCL1 expression ( Fig. 1b and Supplementary  Fig. 11a-c) . Array comparative genomic hybridization analysis demonstrated a high frequency of FBW7 loss 2 but not simultaneous loss of BTRC1 and BTRC2, which encode b-TRCPs, in T-ALL cells (data not shown). Together, these data support the hypothesis that SCF FBW7 is a physiological E3 ubiquitin ligase for MCL1, with USP9X being the nominated deubiquitylase 26 , and that loss of FBW7 contributes to T-ALL development through the upregulation of MCL1 expression. More importantly, our studies suggest that there is a correlation between FBW7 genetic status and sensitivity to ABT-737, and they provide insight into the use of MCL1 inhibitors as a practical method for specifically killing FBW7-deficient T-ALL cells. This work provides a basis for the rational treatment of patients with T-ALL and provides motivation for the development of specific MCL1 antagonists, or agents that significantly reduce MCL1 expression, for the improved management of patients with T-ALL.
METHODS SUMMARY
Expression plasmid constructs, proteins, antibodies and cell lines are described in the Methods. The sequences of various siRNA oligonucleotides used in this study are also listed in the Methods. In vivo phosphorylation of MCL1 was detected by mass spectrometry analysis, and the major GSK3-dependent phosphorylation sites that were identified were subsequently examined by in vitro kinase assays. All mutants were generated using PCR, and the sequences were verified. FBW7mediated MCL1 ubiquitylation and destruction were examined by cell-based ubiquitylation and degradation assays. Cell viability assays were used to detect the response of various T-ALL cell lines to sorafenib and ABT-737. Double staining with annexin V and 7-AAD was used to detect the percentage of apoptotic cells.
